Empagliflozin suppresses urinary mitochondrial DNA copy numbers and interleukin-1β in type 2 diabetes patients

Sodium-glucose co-transporter 2 (SGLT2) inhibitors improve cardiovascular and renal outcomes in type 2 diabetes mellitus (T2DM) patients. However, the mechanisms by which SGLT2 inhibitors improve the clinical outcomes remain elusive. We evaluated whether empagliflozin, an SGLT2 inhibitor, ameliorate...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Haekyung, Kim, Hyoungnae, Jeon, Jin Seok, Noh, Hyunjin, Park, Rojin, Byun, Dong Won, Kim, Hye Jeong, Suh, Kyoil, Park, Hyeong Kyu, Kwon, Soon Hyo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9646895/
https://www.ncbi.nlm.nih.gov/pubmed/36351983
http://dx.doi.org/10.1038/s41598-022-22083-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9646895/
https://www.ncbi.nlm.nih.gov/pubmed/36351983
http://dx.doi.org/10.1038/s41598-022-22083-6

Ejemplares similares